Palbociclib, also known as Ibrance, treats hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. It works by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), which control cancer cell growth. By slowing cell division, palbociclib prevents cancer progression. Learn more at Mayo Clinic and Drugs.com.

Key Benefits & Uses

Palbociclib delivers several benefits:

• Combines effectively with aromatase inhibitors such as letrozole for initial therapy in postmenopausal adults.

• Works with fulvestrant in patients who show disease progression after endocrine therapy.

• Targets HR-positive, HER2-negative advanced or metastatic breast cancer (FDA, WebMD).

How to Use

Take one 125 mg capsule orally once daily for 21 consecutive days, followed by 7 days off. Always take it with food to enhance absorption. Maintain a consistent dosing schedule at the same time each day. For further guidance, consult PubMed and Healthline.

Safety Information

Monitor for neutropenia, a condition that lowers white blood cell counts and increases infection risk. Use effective contraception during treatment and for at least three weeks after the last dose, as palbociclib may harm a fetus. Avoid grapefruit and grapefruit juice because they may interact with the medicine. Regular blood tests help track cell counts and liver function (FDA, WHO).

Common Side Effects

Palbociclib may cause side effects such as neutropenia, anemia, fatigue, nausea, diarrhea, headache, decreased appetite, vomiting, and respiratory infections. Patients should consult Drugs.com or Mayo Clinic for detailed information.

Why Choose Palbociclib

Palbociclib offers targeted therapy for HR-positive, HER2-negative advanced or metastatic breast cancer. Clinical studies show its effectiveness when used in combination therapy. Its structured dosing schedule and support resources make treatment easier to manage (WebMD, PubMed).